Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus InfectionCompleted
NCT04294498Phase 2Updated Jun 30, 2026
Sponsor: National Taiwan University Hospital
Advanced Hepatocellular Carcinoma
Taiwan
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TAREActive Not Recruiting
NCT06040099Phase 2Updated Jun 30, 2026
Sponsor: AstraZeneca
Hepatocellular Carcinoma (HCC)
United States
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate CancerRecruiting
NCT07590934Phase 1, Phase 2Updated Jun 30, 2026
Sponsor: AstraZeneca
Metastatic Prostate Cancer
United States, Australia, Germany, Italy, South Korea +2 more
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)Active Not Recruiting
NCT05925530Phase 2Updated Jun 30, 2026
Sponsor: AstraZeneca
Non-small Cell Lung Cancer
United States, Austria, Canada, Czechia, France +6 more
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)Completed
NCT04609878Phase 3Updated Jun 30, 2026
Sponsor: AstraZeneca
Asthma
United States, Argentina, Belgium, Bulgaria, Canada +16 more
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.Completed
NCT05938270Phase 1Updated Jun 30, 2026
Sponsor: AstraZeneca
Prostate Cancer
United States, Australia, Canada, Netherlands, Spain +1 more
PROLONG (PRostateOLaparibONcombinationGcc) StudyNot Yet Recruiting
NCT07674121N/AUpdated Jun 29, 2026
Sponsor: AstraZeneca
Metastatic Castration-resistant Prostate Cancer (mCRPC)
The Inflammatory Profile of Exacerbations in Patients With Severe Asthma Receiving Tezepelumab: The TezEx StudyCompleted
NCT06666504N/AUpdated Jun 29, 2026
Sponsor: Guy's and St Thomas' NHS Foundation Trust
Severe Asthma
United Kingdom
Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell LymphomaRecruiting
NCT05820841Phase 3Updated Jun 29, 2026
Sponsor: Universität des Saarlandes
Large B-cell Lymphoma · Diffuse Large B Cell Lymphoma
Germany
Observational Study That Will Analyse the Spread and Stratification of Lung Cancer Risk Using Artificial IntelligenceNot Yet Recruiting
NCT07617636N/AUpdated Jun 29, 2026
Sponsor: AstraZeneca
Lung Cancer
Brazil
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruiting
NCT07123454Phase 1, Phase 2Updated Jun 29, 2026
Sponsor: AstraZeneca
B-cell Non-Hodgkin Lymphoma
United States, Australia, China, Italy, Japan +3 more
Trial of Trastuzumab Deruxtecan in Previously Treated HER2Recruiting
NCT06750484Phase 2Updated Jun 29, 2026
Sponsor: Yale University
Breast Cancer Metastatic
United States
A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell MalignanciesCompleted
NCT03198650Phase 1Updated Jun 29, 2026
Sponsor: AstraZeneca
Part1: Advanced B-cell Malignancies · Part2: r/rCLL and r/rMCL · Part3: Untreated CLL
Japan
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/TrixeoRecruiting
NCT07069829N/AUpdated Jun 29, 2026
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease
Argentina, Colombia, Egypt, Indonesia, Jordan +7 more
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney FunctionRecruiting
NCT06307652Phase 3Updated Jun 26, 2026
Sponsor: AstraZeneca
Heart Failure and Impaired Kidney Function
United States, Argentina, Australia, Austria, Brazil +34 more
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.Active Not Recruiting
NCT06268873Phase 3Updated Jun 26, 2026
Sponsor: AstraZeneca
Chronic Kidney Disease and Hypertension
United States, Argentina, Australia, Belgium, Brazil +33 more
TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)Active Not Recruiting
NCT05729711N/AUpdated Jun 26, 2026
Sponsor: AstraZeneca
Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)
Japan
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)Completed
NCT07154901Phase 1Updated Jun 26, 2026
Sponsor: AstraZeneca
Renal Impairment
United States
The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-managementRecruiting
NCT06909773NAUpdated Jun 26, 2026
Sponsor: AstraZeneca
Cardiovascular Diseases
China
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney DiseaseCompleted
NCT06350123Phase 2Updated Jun 26, 2026
Sponsor: AstraZeneca
Chronic Kidney Disease
United States, Austria, Brazil, Bulgaria, Canada +10 more
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaCompleted
NCT03691714Phase 2Updated Jun 26, 2026
Sponsor: Trisha Wise-Draper
Recurrent Head and Neck Cancer · Head and Neck Cancer · Head and Neck Neoplasms · Metastatic Cancer
United States
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung CancerRecruiting
NCT07149363Phase 2Updated Jun 26, 2026
Sponsor: Alliance Foundation Trials, LLC.
Small Cell Lung Cancer (SCLC)
United States
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCCActive Not Recruiting
NCT05557838Phase 3Updated Jun 26, 2026
Sponsor: AstraZeneca
Hepatocellular Carcinoma
China
Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian FederationSuspended
NCT07146113N/AUpdated Jun 26, 2026
Sponsor: AstraZeneca
Prostate Cancer
Russia
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCCCompleted
NCT06366451EARLY_Phase 1Updated Jun 26, 2026
Sponsor: Presage Biosciences
Head and Neck Squamous Cell Carcinoma
United States

Previous page Next page